Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial

Morfin-Otero, Rayo; Noriega, Eduardo Rodriguez; Dowzicky, Michael J.

doi:10.1186/s12941-015-0116-y

Annals of Clinical Microbiology and Antimicrobials

Table 4 Antimicrobial susceptibility [MIC₉₀ (mg/L), % susceptible, % resistant] of carbapenem-resistant gram-negative organisms

From: Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial

Pathogen	2005–2007			2008–2012			2005–2012
Pathogen	MIC₉₀	%S	%R	MIC₉₀	%S	%R	MIC₉₀	%S	%R
Enterobacter spp.	n = 5			n = 14			n = 19
Amikacin	–	[0]	[3]	≥128	64.3	35.7	≥128	47.4	42.1
Amoxicillin-clavulanate	–	[0]	[5]	≥64	14.3	78.6	≥64	10.5	84.2
Ampicillin	–	[0]	[5]	≥64	14.3	85.7	≥64	10.5	89.5
Cefepime	–	[0]	[4]	≥64	50.0	35.7	≥64	36.8	47.4
Ceftriaxone	–	[0]	[5]	≥128	14.3	85.7	≥128	10.5	89.5
Levofloxacin	–	[0]	[5]	≥16	71.4	21.4	≥16	52.6	42.1
Minocycline	–	[5]	[0]	≥32	28.6	42.9	≥32	47.4	31.6
Piperacillin-tazobactam	–	[1]	[4]	≥256	42.9	42.9	≥256	36.8	52.6
Tigecycline	–	[5]	[0]	2	100	0.0	2	100	0.0
E. coli	n = 5			n = 8			n = 13
Amikacin	–	[5]	[0]	–	[2]	[5]	≥128	53.8	38.5
Amoxicillin-clavulanate	–	[1]	[2]	–	[0]	[4]	≥64	7.7	46.2
Ampicillin	–	[3]	[2]	–	[0]	[8]	≥64	23.1	76.9
Cefepime	–	[3]	[1]	–	[1]	[7]	≥64	30.8	61.5
Ceftriaxone	–	[2]	[3]	–	[0]	[8]	≥128	15.4	84.6
Levofloxacin	–	[4]	[1]	–	[0]	[8]	≥16	30.8	69.2
Minocycline	–	[1]	[3]	–	[1]	[6]	≥32	15.4	69.2
Piperacillin-tazobactam	–	[2]	[1]	–	[4]	[4]	≥256	46.2	38.5
Tigecycline	–	[5]	[0]	–	[8]	[0]	2	100	0.0
K. pneumoniae	n = 3			n = 25			n = 28
Amikacin	–	[1]	[0]	≥128	20.0	68.0	≥128	21.4	60.7
Amoxicillin-clavulanate	–	[0]	[3]	≥64	4.0	92.0	≥64	3.6	92.9
Ampicillin	–	[0]	[3]	≥64	0.0	100	≥64	0.0	100
Cefepime	–	[1]	[2]	≥64	12.0	76.0	≥64	14.3	75.0
Ceftriaxone	–	[0]	[3]	≥128	0.0	100	≥128	0.0	100
Levofloxacin	–	[0]	[2]	≥16	4.0	88.0	≥16	3.6	85.7
Minocycline	–	[2]	[0]	≥32	16.0	72.0	≥32	21.4	64.3
Piperacillin-tazobactam	–	[0]	[2]	≥256	8.0	80.0	≥256	7.1	78.6
Tigecycline	–	[3]	[0]	4	84.0	0.0	4	85.7	0.0
S. marcescens	n = 5			n = 13			n = 18
Amikacin	–	[2]	[3]	≥128	38.5	53.8	≥128	38.9	55.6
Amoxicillin-clavulanate	–	[0]	[5]	≥64	0.0	100	≥64	0.0	100
Ampicillin	–	[0]	[5]	≥64	0.0	92.3	≥64	0.0	94.4
Cefepime	–	[2]	[2]	≥64	38.5	46.2	≥64	38.9	44.4
Ceftriaxone	–	[0]	[5]	≥128	23.1	76.9	≥128	16.7	83.3
Levofloxacin	–	[1]	[3]	≥16	23.1	69.2	≥16	22.2	66.7
Minocycline	–	[3]	[1]	≥32	7.7	76.9	≥32	22.2	61.1
Piperacillin-tazobactam	–	[0]	[5]	≥256	23.1	61.5	≥256	16.7	72.2
Tigecycline	–	[4]	[0]	8	84.6	15.4	8	83.3	11.1
Acinetobacter spp.	n = 18			n = 107			n = 125
Amikacin	≥128	22.2	61.1	≥128	8.4	76.6	≥128	10.4	74.4
Cefepime	≥64	11.1	55.6	≥64	9.3	70.1	≥64	9.6	68.0
Ceftazidime	≥64	0.0	94.4	≥64	1.9	95.3	≥64	1.6	95.2
Ceftriaxone	≥128	0.0	100	≥128	0.9	99.1	≥128	0.8	99.2
Levofloxacin	≥16	0.0	66.7	≥16	2.8	90.7	≥16	2.4	87.2
Minocycline	2	94.4	5.6	≥32	64.5	28.0	≥32	68.8	24.8
Piperacillin-tazobactam	≥256	5.6	94.4	≥256	0.9	97.2	≥256	1.6	96.8
P. aeruginosa	n = 75			n = 226			n = 301
Amikacin	64	38.7	42.7	≥128	28.8	55.3	≥128	31.2	52.2
Cefepime	≥64	25.3	60.0	≥64	21.2	61.1	≥64	22.3	60.8
Ceftazidime	≥64	25.3	64.0	≥64	15.9	76.5	≥64	18.3	73.4
Levofloxacin	≥16	26.7	69.3	≥16	19.5	70.8	≥16	21.3	70.4
Piperacillin-tazobactam	≥256	24.0	44.0	≥256	24.8	49.1	≥256	24.6	47.8

When <10 isolates MIC₉₀ data are not presented and the number of isolates susceptible or resistant are presented in parenthesis

Back to article page

ISSN: 1476-0711

Contact us

Submission enquiries: journalsubmissions@springernature.com